The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Are weight loss-approved injectable right for you? On this episode of MorningLine, Nick Bere is joined by Dr. Calvin Smith ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced the powerful effects of this weight loss ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...